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Abstract
Background: All patients with diabetes are at risk of developing diabetic retinopathy (DR), a progressive and
potentially blinding condition. Early treatment of DR prevents visual impairment and blindness. The natural history of
DR is that it is asymptomatic until the advanced stages, thus annual retinal examination is recommended for early
detection. Previous studies show that the uptake of regular retinal examination among people living with diabetes
(PLWD) is low. In the Uptake of Retinal Examination in Diabetes (DURE) study, we will investigate the effectiveness of a
complex intervention delivered within diabetes support groups to increase uptake of retinal examination.
Methods: The DURE study will be a two-arm pragmatic cluster randomized clinical trial in Kirinyaga County, Kenya.
Diabetes support groups will be randomly assigned to either the intervention or usual care conditions in a 1:1 ratio.
The participants will be 700 PLWD who are members of support groups in Kirinyaga. To reduce contamination, the
unit of randomization will be the support group. Peer supporters in the intervention arm will receive training to deliver
the intervention. The intervention will include monthly group education on DR and individual member reminders to
take the eye examination. The effectiveness of this intervention plus usual care will be compared to usual care
practices alone. Participant data will be collected at baseline. The primary outcome is the proportion of PLWD who
take up the eye examination at six months. Secondary outcomes include the characteristics of participants and peer
supporters associated with uptake of eye examination for DR. Intention-to-treat analysis will be used to evaluate the
primary and secondary outcomes.
Discussion: Eye care programs need evidence of the effectiveness of peer supporter-led health education to improve
attendance to retinal screening for the early detection of DR in an African setting. Given that the intervention
combines standardization and flexibility, it has the potential to be adopted in other settings and to inform policies to
promote DR screening.
Trial registration: Pan African Clinical Trial Registry PACTR201707002430195, registered 25 July 2017, www.pactr.org
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Background
The global prevalence of diabetes has escalated in recent
decades, with important implications on the health system.
In 2015 the International Diabetes Federation estimated
that there were 415 million people with diabetes aged 20–
79 years (global prevalence of 8.8%), and this is predicted to
increase to 642 million by 2040 (global prevalence of
10.4%). [1] The incidence and prevalence of diabetes is in-
creasing disproportionately faster in resource-poor regions
and 75% of people living with diabetes currently reside in
low- and middle-income countries. [1–3] This dramatic in-
crease in incidence is occurring in both rural and urban
areas. [4] The regional prevalence for Africa was 3.8% in
2015, and the number of people with diabetes in this con-
tinent is expected to increase by 140% between 2015 and
2040. [1] In Kenya, the STEPwise survey for risk factors of
non-communicable diseases in 2015 found a diabetes
prevalence of 2% in the population 18–69 years, and 5.4%
in the population 45–59 years. [5]
All patients with diabetes are at risk of developing dia-
betic retinopathy (DR), the most severe and progressive
ocular complication of diabetes. One third of patients
with Type 2 diabetes have DR while 10% of them have
sight-threatening DR, which represents a significant
public health concern. [6, 7]. A population-based study
in Nakuru county, Kenya found that 35.9% of people liv-
ing with diabetes (PLWD) have DR [8]. Visual impair-
ment and blindness from DR is preventable mainly
through early detection and timely treatment. Since DR
is asymptomatic until the advanced stages, regular ret-
inal screening is of paramount importance. DR meets
the Wilson and Jungner (1968) criteria for screening,
and current clinical guidelines support annual screening
[9–12]. Participation of PLWD in regular retinal screen-
ing, has been shown to be clinically effective in prevent-
ing blindness and is also cost-effective. [13, 14]
In developed countries, health systems have formal sur-
veillance programmes for detection of DR. Kenya does not
have a national population-based DR screening service
where PLWD are systematically invited for screening, but
opportunistic screening is available in various hospitals.
Importantly, participation and re-participation rates in
screening for DR are sub-optimal in Kenya and other re-
source poor settings. [15–22]. The determinants of the at-
tendance to retinal examination are complex and include
both supply and demand factors. [23, 24] For instance, a
Tanzanian study found that PLWD also have limited
awareness on diabetic retinopathy, particularly on the
need for annual eye examination [25]. This is a barrier
that appropriate demand side interventions could address.
A health system assessment conducted before this study
has shown that 87% of PLWD in Kenya have an unmet
need for annual retinal screening. [22] One of the gaps as-
sociated with this is the lack of strong links between
diabetes services and eye care services. There is need for
context-specific pragmatic solutions to address this gap.
A systematic review of interventions to increase diabetic
retinopathy screening attendance reported that several
strategies are effective, including those targeting the pa-
tient (e.g. increasing patient awareness), the health care
practitioner (e.g. improving adherence to recommenda-
tions) or the organization (e.g. improving patient records)
[26]. Members of diabetes support groups (DSGs) are a
population subgroup that might benefit from additional
support to initiate screening, and adhere to re-screening.
Targeting screening interventions towards PLWD in DSGs
provides a timely opportunity for three reasons. Firstly this
is a community resource that is already available in the
community setting. Secondly this population is likely to
consider health as an important rationale for behaviour
change and the health seeking behaviour of members is
potentially malleable to change through peer support. Peer
support refers to the provision of emotional and informa-
tional support from a created social network member who
is considered an equal and who has characteristics similar
to the target population. [27] Thirdly it is an economical,
culturally-sensitive and flexible intervention for improving
diabetes care and outcomes. [28, 29]
Self-efficacy is a direct predictor of health behaviour, ac-
cording to the social cognitive theory and the self-efficacy
theory [30] [31]. Self-efficacy is a predictor of uptake of
screening for DR among PLWD. [32] Interventions that
improve patients’ self-efficacy decrease perceived barriers
and improve the likelihood of initiating the desired health
behaviour. There are four main sources of self-efficacy [31]:
(i) Successful performance accomplishments (e.g. having
attended a previous eye examination) (ii) vicarious experi-
ence (e.g. learning that peers have successfully attended an
eye examination) (iii) verbal persuasion (e.g. encouragement
and recommendation to go for an eye examination by a
trusted person, such as a peer or a health care worker) and
(iv) psychological cues (decreased sense of isolation of
PLWD interacting with a peer, or increased awareness of
the risk of DR after receiving educational messages on DR).
Fig. 1 shows how self-efficacy for taking a retinal examin-
ation might improve through peer support in the Uptake of
Retinal Examination in Diabetes (DURE) study.
Rationale
Although there is evidence that peer support improves
glycaemic control and quality of life among adult PLWD,
and that peer support is both cost-effective and flexible
[33], evidence on whether or not it would increase uptake
of eye examination in an agrarian African population is
lacking. DURE study aims to provide this evidence.
The development of the intervention has been in-
formed by the following:
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i. A review of the literature on peer support in diabetes
[34–42] and other chronic conditions in resource
poor settings. [43–51] There is evidence that peer
approach is widely used in the management of
diabetes, to promote physical activity, healthy eating
and improvemt in glycaemic control.
ii. The results of a recent published meta-analysis of
randomized clinical trials on effectiveness of
peer-support for glycaemic control in Type 2
diabetes [52] which concluded that peer support
had a significant impact on improving HbA1c
levels in patients with poor glycaemic control.
iii. A health system assessment in three counties of
Kenya conducted before this study showed that
services for DR are underutilised: 74% of PLWD
have never had a retinal examination in their
lifetime, and 76% have never had a recommendation
for an eye examination by their diabetes care
provider [22].
iv. Evidence that improving health literacy, provider
patient interaction and linking patients to health
care improves patients’ self-efficacy and glycaemic
control. [42, 53, 54]
Aim
To evaluate, by means of a pragmatic cluster randomized
controlled trial, the effectiveness of a peer supporter- led
community education programme in Kirinyaga county,
Kenya.
Research questions
1. To what extent can health education delivered by
peer supporters increase the demand for annual
retinal examination among PLWD?
2. What are the contextual factors that determine the
effectiveness of the intervention?
Hypothesis
The hypothesis is that the proportion of PLWD having a
retinal examination for DR is higher in diabetes support
groups (DSGs) allocated to the peer supporter-led edu-
cational package than in DSGs randomized to the usual
standard of care.
Methods
Design
This is a two-arm pragmatic cluster randomized con-
trolled trial with additional process evaluation. It is a
complex intervention to empower patients to undergo
an annual eye examination. It is complex because those
delivering and receiving the intervention require to dem-
onstrate different behaviours and to engage in multiple
interactions. [55] Its design is guided by the Medical Re-
search Council framework for complex interventions,
Fig. 1 Peer support and self-efficacy for retinal examination
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available at https://mrc.ukri.org/documents/pdf/com-
plex-interventions-guidance/ [55].
The study will be conducted in accordance with the
Consolidated Standards of Reporting Trials (CONSORT)
2010 statement and its extension to cluster randomized
clinical trials (cRCTs). [56, 57] The cRCT design is
adopted for the following reasons: (i) to reduce the effect
of intervention contamination, as compared to an indi-
vidually randomised trial, as patients in the same DSG
often interact with one another (ii)to make it feasible to
study the effect of the intervention at the individual level
and the cluster level.
Definition of eye examination for DR
We define this test as: measurement of visual acuity and a
retinal examination through a dilated pupil conducted by
an eye care worker (using either an ophthalmoscope, a slit
lamp or a retinal camera). Retinal examination for DR and
DR screening in this protocol are used interchangeably.
Study setting
This trial will be conducted among the DSGs in Kiri-
nyaga county, Kenya. The target population is members
of the 16 support groups and volunteer peer supporters
within these groups. Eye examination will be conducted
at Kerugoya County Referral Hospital.
Sample size calculation
We aim to randomize seven diabetes patient support
groups (clusters) with an average membership of 50 each
to each arm. The study thus has two arms of equal size
(350 participants in each arm).This sample size has been
calculated using standard formula for sample size for
cRCTs and taking into consideration the primary outcome
of interest [58, 59]. A 15% loss to follow-up contingency
has been built into the sample size calculation. This sam-
ple size would have 80% power to detect a two-fold differ-
ence in the proportion of PLWD who take up eye exam,
with a 5% level of significance. Member registers of the
DSGs will be obtained from the team lead. These registers
will be the frame for identification of participants for the
study.
Pilot study
A pilot study will be conducted in two clusters with 50
PLWD in each arm (intervention arm and control arm), se-
lected through convenience sampling. The pilot will be
conducted for 3 months and will involve: Testing study op-
erational procedures; Implementation of the intervention in
the intervention clusters; Testing study instruments for
quantitative and qualitative data collection (questionnaires,
observation sheets and topic guides); Outcomes evaluation.
The primary outcome will be the proportion of participants
in each arm that take up eye examination.
Inclusion and exclusion criteria
Participants will be included if they are PLWD aged 18+
years, will reside in Kirinyaga for the next 12 months,
are members of DSGs in Kirinyaga, have a mobile phone
and are willing to participate in the study. In addition to
these criteria, peer supporters will be selected from
those willing to participate as peer supporters, willing to
commit two days for training and many hours of peer
support, fluent in Kikuyu or Kiswahili, and have had a
retinal examination for DR before the start of the study.
PLWD who will be excluded are those already attending
annual retinal screening, have a severe debilitating med-
ical condition, are already on treatment for DR or do
not meet the inclusion criteria.
Recruitment
Eligible participants will be recruited into the study by the
research nurse, who will also obtain informed consent at
the cluster level using the consent form approved for the
study. Participants will be asked for consent to receive the
intervent ion and for follow up. If the patient does not
consent, reasons will be sought and recorded. After re-
cruitment, a unique identifier number will be issued. All
those recruited will be given an identification card which
contains the name and a unique study number. They will
be required to present this card at the eye clinic when they
go for retinal examination. The flow diagram for the study
is presented in Fig. 2.
Randomization
Randomization will be done after recruitment. The
randomization will be through computer generated random
numbers prepared by a statistician (DM) using STATA ver-
sion 15 (StataCorp 2017), away from the project site. The
allocation sequence will be concealed from the other trial
personnel. Block randomization with block sizes of two or
four will be used to ensure that the two arms are balanced
over time, and to maintain unpredictability of allocation.
Masking will not be possible but only the research team will
have formal knowledge of the allocation.
Intervention
Two peer supporters will be recruited from each cluster in
the intervention arm (one male and one female). These
peer supporters will be selected from volunteers who meet
the specified criteria. They will receive structured training
in a two-day workshop. The content of the training ses-
sions includes: an introduction to the project, the role of
the peer supporter, diabetic eye disease and DR, retinal
examination for DR, communication skills, managing
groups, confidentiality and behaviour change. The training
team will include a certified diabetes educator.
They will receive support to retain them in the study
(airtime vouchers for delivering the telephone reminders).
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Fig. 2 Flow diagram for the trial
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They will also receive a weekly telephone call from the
principal investigator for support. The intervention group
will receive the usual care, a monthly group talk and a
monthly individual telephone reminder to attend retinal
examination. The key messages to be delivered in the
group talk are shown in Table 1. The control group will
receive the usual standard of care, which consists of ad
hoc diabetes educational talks, blood sugar and blood
pressure measurements during support group meetings.
Data collection
Standardized operating procedures will be used to col-
lect data at baseline, using approved tools in the study
proposal. Demographic and anthropometric (height,
weight, waist circumference) as well as blood pressure,
blood sugar and visual acuity will be recorded at base-
line. Study participants will be given their body mass
index and blood pressure measurements in the field, at
the point of data collection; where these results are ab-
normal, participants will be referred to a health worker.
Completed questionnaires will be monitored and data
entry staff will be trained to minimize errors in data
entry into computerized databases. Identifiers will be re-
moved from participant data, and all paper data will be
stored in locked cabinets. Electronic data will be pass-
word protected for confidentiality. A detailed data man-
agement plan is included in the study proposal.
Follow up
Participants in both arms will be followed up for six
months to assess attendance to retinal examination. Par-
ticipants who are lost to follow up will be identified at
the monthly contact points with peer supporters. Three
home visits will be made to trace participants who are
lost to follow up. Characteristics of those lost to
follow-up and reasons for loss will be evaluated.
At the end of six months two separate focus group dis-
cussions will be held with two participants from each
intervention cluster in each arm (n = 14 for each focus
group discussion) to explore the experience of the support
groups with the intervention. A focus group discussion
will also be held with peer supporters to explore the im-
pact of ‘peer supporting’ on the management of their own
diabetes, and their role in the health care team.
Process evaluation
A process evaluation will be conducted using qualitative
interviews and non-participant observation (Table 2).
The findings of the process evaluation will be evidence
Table 1 Key messages to be delivered to participants
Messages on diabetic eye disease
1 Diabetes causes several complications in the eye, including DR
2 DR is a progressive condition that leads to blindness if treatment is not provided in good time
3 DR has no symptoms until the advance stages
4 An eye check by an eye specialist can detect damage to the eyes before symptoms develop
5 All persons with diabetes should have their eyes checked once every year by an eye specialist, even before any symptom or
poor vision develops
6 Do not wait for your vision to get worse or for any other symptom to occur before you see an eye specialist
7 If eyes are found to be normal at your eye check by an eye specialist, please continue with an eye check annually
8 If you notice any abnormality with your eyes between your clinic appointments, visit the eye specialist as soon as possible.
It may not mean that you have diabetic eye disease, it may be a simple problem that requires treatment.
9 The eye check may help to determine if your sugar, blood pressure, and lipid control needs to be re-assessed.
Good control of your blood sugar levels, blood pressure and cholesterol reduces the risk of diabetes-related sight loss.
10 If you are found to have DR the eye specialist will inform you about the diagnosis, and how it will be treated.
Messages on retinal examination for DR
1. Ensure you have a dilated eye examination at the eye clinic at least once a year.
2. You do not need to have a referral note to go to the clinic. However we will give you a card to present at the clinic.
3. At the eye clinic, your vision will be checked first.
4. A examination for DR is different from any other type of eye examination. It is called a dilated eye examination.
5. In this examination, the doctor puts eye drops into your eyes to dilate (widen) your pupils. This allows the doctor to
have a good view of the back of the eye. Both eyes need to be examined.
6. The examination is not painful. When the eye drops are first instilled, there may be a slight stinging sensation but
this only lasts about a minute. You may feel uncomfortable because of light sensitivity and blurred vision once the pupils are dilated.
7. Do not be afraid to ask the doctor questions about the examination or about diabetic eye disease.
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on why and how the intervention worked. The following
domains of the intervention will be evaluated:
1) Whether the intervention activities are
implemented as planned (fidelity).
2) The extent to which the intervention reaches the
PLWD (reach).
3) The degree to which PLWD are exposed to the
intervention package (dose).
4) The extent to which the intervention is acceptable
to PLWD and to eye care workers (acceptability).
5) The contextual factors that may have an influence
on the theory of change (context).
Assessment of outcome
Primary outcome
Rates of eye examination in each arm will be assessed in
each arm at the end of six months. This outcome will be
assessed by an independent and masked research nurse
who will review the eye clinic records of all participants.
The outcome will be recorded on the outcome evalu-
ation form for each participant. The form contains iden-
tification details of each participant recruited into the
study (name, residence, telephone number) and will thus
differentiate them from other patients who are examined
in the eye clinic. The form does not contain information
on the intervention arm to which the patient is allo-
cated. The project manager will receive the completed
outcome evaluation forms and link the data to the par-
ticipant database for each arm.
Secondary outcomes
These outcomes will be assessed at six months:
1. Contextual factors that affect the effectiveness of
the intervention
2. Characteristics of peer supporters associated with
uptake of eye examination
3. Barriers to uptake of eye examination among
PLWD.
These outcomes will be evaluated using the database
for participants and peer supporters, as well as data from
focus group discussions with peer supporters and
in-depth interviews with eye care workers at six months.
Statistical analysis
Baseline comparability of the two groups will be assessed
to check that the important confounders and baseline
characteristics that would affect uptake of eye examin-
ation are balanced between the two arms through ran-
domisation. If the arms are found to be substantially
Table 2 Domains and methods for process evaluation
Source Domain Data collection method Stage of the trial
Trial registers Recruitment Retention Registers in the trial office Throughout the trial (n = 700)
Participants Fidelity
Reach
Dose received
Effectiveness
Participant Questionnaire
2 Focus group discussions at
6 months
At recruitment (n = 700)
Three months: n = 10% pf participants
in each intervention cluster(35)
Six months: n = 10-% of participants in
each cluster (35)
N = 28
Non-participant observations by
PI
Recruitment
Fidelity
Dose delivered
Context
PI Field notes N = 2 group meetings per intervention
cluster during the trial (14)
Peer supporters (PS) Effectiveness
Reach
Fidelity
Dose delivered
Context
PS Questionnaires
PS Diary for telephone calls
PS Group session report form
Focus group discussion at 6 months
After training (n = 14)
Through the trial (n = 14)
Throughout the study (1 report form
per group meeting per PS)
N = 7
Eye care workers
Key informants
Context In-depth interviews At 6 months
N = 3
N = 7
Research project manager Reach
Fidelity
Dose delivered
Reports At recruitment of PS
At training the PS
At 3 and 6 months
Research nurse Outcome evaluation
procedures
Report At 3 months and 6 months
Study steering committee Context Spreadsheet of external events that
may have affected study outcomes
At 6 months
PI Principal Investigator, PS Peer supporter
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imbalanced an appropriately adjusted logistic regression
model will be used.
Study-wide pooled analysis will be conducted for the
primary outcome. Missing data will be reported using
standard flow charts. Repeated measures mixed models
regression with adjustment for age, sex, and baseline an-
thropometric measures will be used to compare the two
groups for the primary outcome.
Analysis will be conducted on intention-to-treat basis.
Regression analysis will be used to determine the extent to
which individual and support group characteristics are as-
sociated with the primary outcome. Models for comparing
continuous outcomes will use linear regression while
models for categorical outcomes will use logistic regression.
Kaplan-Meier analysis will be used to plot the survival
curves for both treatment arms. Cox regression will be used
to assess the impact of the intervention on time to first eye
examination. The hazard ratio will be estimated with Cox
regression, adjusting for substantial baseline imbalances if
appropriate. Interim analysis is not planned.
Data monitoring
The principal investigator will coordinate and monitor
all recruitment, intervention and follow up procedures.
A data monitoring committee will not be required.
There is no reason to expect significant adverse effects
and there are no stopping rules. The principal investiga-
tor will have access to all the trial data sets.
Harms
Neither arm of the trial has serious anticipated harms. The
retinal examination involves the use of mydriatic eye drops.
This may cause temporary blurring of vision, but this is
only expected to last for a few minutes or hours. In this trial
the drugs will be instilled by highly experienced clinicians,
and patients will be made aware of this effect beforehand.
Any unexpected effects of the trial will be documented and
reported to the sponsor and ethics committees.
Dissemination
The dissemination strategy will include a summary of
the findings for support groups, a report to Kerugoya
County government and the Ministry of Health Kenya,
publications in peer-reviewed journals and presentations
at national and international conferences.
Post-trial care
It is recommended that all PLWD have an annual retinal
examination for DR, and more frequent examinations
are required for those found to have any stage of DR.
This is best practice that is recommended by the na-
tional guidelines for screening and management of DR
in Kenya. [12] The service will continue to be available
as routine care to PLWD at the Kerugoya County Refer-
ral Hospital beyond the study.
Discussion
This study is pragmatic in that it tests the effectiveness
of this intervention in the real-world situation of the
community and the health system in Kirinyaga. There is
a strong need to develop interventions that can reach
PLWD populations in real world settings to ensure that
any effect found is generalizable.
Public health strategies to manage the diabetes and DR
in sub-Saharan Africa (SSA) are known to be inadequate
or non-existent. [60, 61] Given that we are at the emer-
gence of the epidemic, this is an appropriate time to de-
velop contextual interventions that will enable our health
system to cope with this challenge. To our knowledge, this
is the first study that has targeted the DSG population in
DR research. The use of peer support in DR is a relatively
new field and little has yet been published on the topic.
The trial is important for a number of reasons. For the
individuals with diabetes, this trial is in line with the
growing global focus on patient empowerment. The
PLWD will be empowered to demand for retinal exam-
ination, thus reducing demand side barriers to uptake of
the examination. These actively engaged PLWD will be
linked to eye care providers by the peer supporters. The
Chronic Care Model, which has been proposed as a suit-
able model for managing diabetes, emphasises on the
need to implement such links between patients and the
health system using community resources. [62] [47] As
all PLWD are at risk of DR, empowerment to initiate
and maintain screening will be beneficial to all.
For the support groups, if this intervention positively in-
fluences uptake of retinal examination, this could in turn
influence how the DSGs define their role. It has potential
to instigate a new agenda, making the groups key sites for
preventive public health initiatives that are adaptable, feas-
ible and embedded within support group culture. The
peer supporters will remain a valuable resource in the
DSG, which enhances sustainability of effect.
For Kirinyaga county, our study findings might help
the county (formerly district) health services to develop
initiatives to promote early detection of DR, by involving
DSGs, empowering patients and developing effective re-
ferral systems for DR services. The role the support
groups can play in strengthening the health system for
diabetic retinopathy in the county will become explicit.
The intervention will be provided by trained peer sup-
porters, which is a form of task-shifting. Task shifting is com-
monly applied in both diabetes and eye care services in our
setting. It helps to address the severe shortage of human re-
sources for health. The peer supporters will refer patients to
the eye clinic, thus linking diabetes patients with eye clinics
and strengthening the referral system in the county.
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In national context, Kenya aims to achieve universal
eye health, which includes care for DR. This study pro-
vides a framework for the promotion of retinal screening
in the population with the risk of developing DR. If ef-
fective, the intervention would be a sustainable and scal-
able to other countries.
In the international contexts, the DURE study has the po-
tential to extend current evidence and inform the scientific
debate as to whether embedding retinal screening into
DSGs is an effective next step toward meeting health goals.
The explicit use of a theoretical construct (self-efficacy
theory) to conceptualise the potential determinants that
would influence attendance to DR screening is a key
strength of the study. It enhances the understanding of
the plausibility of the intervention. The intervention pack-
age combines both standardization and flexibility, which
allows for scalability in diverse settings. A further strength
of this study is the inclusion of process evaluation, which
will assist in the interpretation of how and why the inter-
vention did, or did not, bring about the predicted effects.
The study has potential limitations. There are only 16
support groups in the county, which limits the possibil-
ity of increasing the number of clusters to further en-
hance statistical power. Delayed recruitment of the
required sample size and loss to follow-up during the
trial may be a challenge. In mitigation, a 15% loss to
follow-up contingency has been built into the sample
size calculation. Sample attrition can result from any in-
accuracies in the data collection, such as incorrect ad-
dress and telephone number information. Other diabetes
studies have documented that patients were unable or
unwilling to participate due to transportation issues and
lack of time or interest [63]. However this is not antici-
pated because: alternative contact information of partici-
pants will be documented, only one visit to the eye
clinic is required of participants, and the intervention is
expected to build participants’ self-efficacy. Attrition bias
may occur if whole clusters drop out, however this is
not anticipated as the study period is short.
Despite these limitations, DURE study illustrates the tre-
mendous potential of implementing pragmatic cluster
RCTs in the diabetes support group setting. Implementing
the trial in this at-risk population will be an invaluable
learning opportunity. Many of the lessons learned from
this experience could be useful to other research projects.
Trial status
At the time of submission, the trial is at the stage of
enrolment.
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